

PRESS RELEASE 13th MARCH 2012

MOBERG DERMA ACTIVATES DEFERRED TAX ASSETS

The Board of Moberg Derma AB (OMX: MOB) considers it as probable that future taxable profit will be available and can be utilized against unutilized tax losses. This tax receivable is reported both in the income statement and balance sheet, resulting in a positive impact first quarter 2012 by SEK 31.8 million. The Company has outstanding tax loss carryforward of 120.8 million.

"We have achieved strong sales growth for Nalox™/Emtrix[®] and new agreements and product launches creates opportunities for an international expansion and continued strong growth with profitability", say Peter Wolpert, CEO and founder of Moberg Derma.

About this information

Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am (CET) on March 13th, 2012.

For further information, please contact:

Peter Wolpert, President and CEO Telephone: +46 8 522 307 00

Mobile: +46 735 71 35

E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR Mobile: +46 73-355 26 01

E-mail: magnus.persson@mobergderma.se

About Moberg Derma

Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company's products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma's first product NaloxTM/Emtrix[®] - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The share of Moberg Derma is quoted on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.se